Abstract Number: 1317 • ACR Convergence 2021
Impairment of Memory in Axial Spondyloarthritis?
Background/Purpose: There is certain evidence that neuropsychiatric changes occur in systemic lupus(1) and rheumatoid arthritis (2). However, there is little knowledge about possible cognitive changes…Abstract Number: 1337 • ACR Convergence 2021
Long-Term Safety Data for IL-12/23 Inhibitor (Ustekinumab) or Tumor Necrosis Factor Inhibitor in Patients with Psoriatic Arthritis from a Real-World Study
Background/Purpose: Psoriasis and PsA are associated with multiple comorbidities such as cardiovascular disease and metabolic syndrome. These comorbidities may render patients prone to developing adverse…Abstract Number: 1354 • ACR Convergence 2021
Differences in Real-World Patient Characteristics of 8921 Patients with Psoriasis with and Without Comorbid Psoriatic Arthritis Using the UK BADBIR Database
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis (PsO) and multiple comorbidities.1 Approximately one-third of patients with PsO develop PsA during…Abstract Number: 1722 • ACR Convergence 2021
Risk of Pre-eclampsia and Impact of Disease Activity and Anti-rheumatic Treatment in Women with Rheumatoid Arthritis, Axial Spondylarthritis, and Psoriatic Arthritis – A Collaborative Matched Cohort Study from Sweden and Denmark
Background/Purpose: Pre-eclampsia is a pregnancy-related syndrome with potentially fatal outcomes. In RA, high disease activity has been associated to adverse pregnancy outcomes such as preterm…Abstract Number: 1789 • ACR Convergence 2021
Prediction of Psoriatic Arthritis in Patients with Psoriasis Using DNA Methylation Profiles
Background/Purpose: Psoriatic arthritis (PsA) poses an immense clinical burden with significantly increased morbidity and mortality risk compared to psoriasis alone. PsA may develop in 30%…Abstract Number: 1806 • ACR Convergence 2021
Designing a Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Guselkumab (TREMFYA®/sup>) Dosing Interval in Psoriatic Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibition
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are frequently chosen as the first biologic therapy for patients (pts) with PsA, though a sizeable proportion of pts…Abstract Number: 1824 • ACR Convergence 2021
Secukinumab Treatment Provides Sustained Resolution of Enthesitis at Individual Joints Through 52 Weeks in a Phase 3b, Double-Blind, Randomized, Active-Controlled Study
Background/Purpose: Enthesitis is a key musculoskeletal manifestation of psoriatic arthritis (PsA). In the double-blind, head-to-head EXCEED study (NCT02745080), although the primary endpoint of superiority of…Abstract Number: 1945 • ACR Convergence 2021
Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from Two Phase 3 Studies
Background/Purpose: Patients with PsA and axial involvement have higher disease activity and greater reductions in quality of life;1 however, there are no accepted criteria for…Abstract Number: 0135 • ACR Convergence 2021
Comparing Rheumatoid Arthritis (RA), Psoriatic Arthritis (PA) and Systemic Lupus Erythematosus (SLE) Total Cost of Care (TCC) in Those with Optimally Managed Depression to Those with Sub-optimally Managed Depression
Background/Purpose: Rheumatic diseases (RD) are characterized by systemic signs and symptoms, including articular and extra-articular manifestations. Three common forms of RDs are RA, PsA and…Abstract Number: 0490 • ACR Convergence 2021
Biomarker Changes with Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in PsA: Effects on Disease Markers and Tyrosine Kinase 2‒ versus Janus Kinase 1/2/3‒mediated Pathways
Background/Purpose: Deucravacitinib is a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action that has demonstrated efficacy in patients (pts)…Abstract Number: 0944 • ACR Convergence 2021
A Characterization of the Gut and Cutaneous Microbiome of Monozygotic Twins Discordant for Psoriatic Disease
Background/Purpose: Psoriasis (PsO) is an inflammatory, immune-mediated skin disorder affecting ~3% of the population worldwide. It is associated with multiple comorbidities, including psoriatic arthritis (PsA),…Abstract Number: 1319 • ACR Convergence 2021
Cardiovascular Risk Reclassification According to Six Traditional Cardiovascular Risk Algorithms and a Carotid Ultrasound in Psoriatic Arthritis Patients
Background/Purpose: Patients with psoriatic arthritis (PsA) have a higher risk of developing a cardiovascular (CV) event than the general population. This could be attributed to…Abstract Number: 1338 • ACR Convergence 2021
Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naïve Populations from a Phase 2b Open-Label Extension Study
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, and has demonstrated clinical improvements in joint and skin outcomes…Abstract Number: 1355 • ACR Convergence 2021
Psoriatic Arthritis Incidence Among Patients Receiving Biologic Medications for Psoriasis; A Nested Case Control Study
Background/Purpose: The objective of this study was to investigate the effect of biological treatments for psoriasis on the incidence of psoriatic arthritis.Methods: A retrospective cohort…Abstract Number: 1738 • ACR Convergence 2021
Uveitis Status in Patients with Ankylosing Spondylitis or Psoriatic Arthritis Under Secukinumab Treatment – Real World Data from a German Observational Study
Background/Purpose: Uveitis is a well-known non-musculoskeletal manifestation of spondyloarthropathies. Patients typically suffer from blurred vision, pain, and photophobia and have an increased risk of ocular…
- « Previous Page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- …
- 81
- Next Page »